Effects of a novel hepatitis B anti-viral drug E-CFCP in renal organic acid transporters.
Effects of a novel hepatitis B anti-viral drug E-CFCP in renal organic acid transporters.
复制标题
DOI：
10.1016/j.jphs.2022.09.002
复制
发表时间：
2022-12
影响因子：
3.5
通讯作者：
Anzai, Naohiko
中科院分区：
文献类型：
--
作者：
Ishibane, Misaki;Hashimoto, Hirofumi;Kaneko, Meika;Saito, Shota;Pae, Sangjon;Saito, Shinpei;Reien, Yoshie;Hirayama, Yuri;Higashi-Kuwata, Nobuyo;Mitsuya, Hiroaki;Anzai, Naohiko
目前，耐药性的出现是B型肝炎病毒（HBV）治疗中的一个重要问题。最近，我们的合作小组开发了一种新型的长效抗HBV药物E-CFCP。然而，直到这项研究，E-CFCP在肾脏中的作用仍然不清楚。利用细胞活力和摄取测定，我们研究了E-CFCP对肾有机阴离子转运蛋白（OAT）功能的影响。在任一试验中，肾脏OAT中均未显示与E-CFCP相关的细胞毒性。因此，本研究表明，E-CFCP可能是一种新的，优秀的候选药物，用于治疗耐药HBV。
Currently, the emergence of drug resistance is an important issue in the treatment of hepatitis B virus (HBV). Recently, our collaborating group developed a novel long-acting anti-HBV drug, E-CFCP. However, until this study, the effects of E-CFCP in the kidney have remained unclarified. Using cell viability and uptake assays, we examined the effects of E-CFCP on the function of renal organic anion transporters (OATs). No cytotoxicity was shown related to the E-CFCP in the renal OATs in either assay. Thus, this study suggested that E-CFCP may be a novel, excellent candidate drug for the treatment of drug-resistant HBV.